ArticleThe Journal of veterinary medical science2025
Urinalysis of a Hantaan virus-infected mouse model of hemorrhagic fever with renal syndrome.
Article in The Journal of veterinary medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hantaan virus causes hemorrhagic fever with renal syndrome (HFRS), a rodent-borne zoonotic disease. Korean hemorrhagic fever virus (KHFV), a strain of Hantaan virus, showed symptoms in mice similar to those of HFRS patients, including weight loss, renal medullary hemorrhage, hepatitis, and neutrophilia. Therefore, mice inoculated with KHFV were expected to serve as a model for HFRS. However, urinary symptoms characteristic of HFRS, such as proteinuria and hematuria, have not yet been examined. In this study, we attempted to evaluate renal function by analyzing urine. As a result, in mice inoculated with KHFV, oliguria and hematuria accompanied by weight loss were observed at 5-8 days after inoculation, and albuminuria was also observed. In addition, the viral load in the kidney and viral excretion into the urine were observed. When the neutralizing monoclonal antibody HCO2 against Hantaan virus was administered before inoculation, all symptoms were abolished. To clarify the therapeutic effect of HCO2 antibody, it was administered intravenously on days 1, 3, and 5 after infection. Weight loss and renal medullary hemorrhage were suppressed, and histological examination revealed micro renal hemorrhage in mice on day 5 administration. It was found that neutralizing antibody can be expected to alleviate symptoms even if it is administered late, and that early administration is more effective. These results indicate that this mouse model shows symptoms like human HFRS and can be used to evaluate antiviral effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.